AC Immune SA (ACIU) News
Filter ACIU News Items
ACIU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACIU News Highlights
- ACIU's 30 day story count now stands at 6.
- Over the past 10 days, the trend for ACIU's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AC, ACI and PRTA are the most mentioned tickers in articles about ACIU.
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune Announces Pricing of Underwritten Offering of Common SharesAC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting |
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b TrialAC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive |
AC Immune SA's (NASDAQ:ACIU) top owners are private equity firms with 37% stake, while 25% is held by individual investorsKey Insights Significant control over AC Immune by private equity firms implies that the general public has more power... |
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityBiogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. |
Alzheimer's Disease Space Evolves in 2023: Stocks in FocusThe approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines. |
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move. |
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOAC Immune appoints Madiha Derouazi as CSO Dr. Madiha Derouazi appointed as new CSO of AC Immune AC Immune appoints Christopher Roberts as CFO Christopher Roberts confirmed in CFO role on a permanent basis AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Ch |
Penny Stock Powerhouses: 7 Picks Poised for Explosive GrowthUndeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. |
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year. |
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successBreakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. |